Fusion Genomics Receives $1 Million Award to Evaluate Novel Genomic Diagnostics Platform in Collaboration with Sunnybrook Research Institute
Fusion Genomics announced that the company has been awarded $1 million to conduct a prospective clinical study evaluating its ONETest™ comprehensive, novel genomic diagnostics platform. The study is funded through the CQDM Quantum Leap program, which supports exploration of innovative technologies, tools, and platforms that accelerate or facilitate drug discovery and development. Merck is supporting the study as a member of CQDM, and Fusion Genomics will collaborate with Sunnybrook Research Institute to conduct the study.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
